Advertisement

Topics

PubMed Journals Articles About "Serum Brain Natriuretic Peptide Levels And Pulmonary Hypertension In Pediatric Sickle Cell Patients" RSS

21:25 EDT 21st August 2018 | BioPortfolio

Serum Brain Natriuretic Peptide Levels And Pulmonary Hypertension In Pediatric Sickle Cell Patients PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Serum Brain Natriuretic Peptide Levels And Pulmonary Hypertension In Pediatric Sickle Cell Patients articles that have been published worldwide.

More Information about "Serum Brain Natriuretic Peptide Levels And Pulmonary Hypertension In Pediatric Sickle Cell Patients" on BioPortfolio

We have published hundreds of Serum Brain Natriuretic Peptide Levels And Pulmonary Hypertension In Pediatric Sickle Cell Patients news stories on BioPortfolio along with dozens of Serum Brain Natriuretic Peptide Levels And Pulmonary Hypertension In Pediatric Sickle Cell Patients Clinical Trials and PubMed Articles about Serum Brain Natriuretic Peptide Levels And Pulmonary Hypertension In Pediatric Sickle Cell Patients for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Serum Brain Natriuretic Peptide Levels And Pulmonary Hypertension In Pediatric Sickle Cell Patients Companies in our database. You can also find out about relevant Serum Brain Natriuretic Peptide Levels And Pulmonary Hypertension In Pediatric Sickle Cell Patients Drugs and Medications on this site too.

Showing "Serum Brain Natriuretic Peptide Levels Pulmonary Hypertension Pediatric" PubMed Articles 1–25 of 34,000+

Biomarker and shear stress in secondary pediatric pulmonary hypertension

Background/aim: Endothelial dysfunction, tissue damage, inflammation, and microthrombosis are involved in the pathogenesis of pulmonary hypertension (PH), which may be present as a complication of congenital heart diseases. This study aims to identify how indicators of endothelial dysfunction (shear stress), tissue damage (brain natriuretic peptide and troponin T), inflammation (C-reactive protein (CRP)), and microthrombosis (D-dimer and von Willebrand factor) are altered in children with congenital left-to...


Using changes in pro-brain natriuretic peptide of plasma amino-terminal and norepinephrine levels as prognostic and diagnostic factors in hand-foot-and-mouth disease.

We explored the possibility of using the variations in the pro-brain natriuretic peptide (NT-proBNP) of serum amino-terminal and norepinephrine (NE) levels as prognostic as well as diagnostic factors in children suffering from severe hand-foot-and-mouth disease (HFMD).

Acute effects of insulin on circulating natriuretic peptide levels in humans.

The natriuretic peptide hormones play an important role in salt and blood pressure regulation. In observational studies, obesity and insulin resistance have been consistently associated with lower concentrations of natriuretic peptides. It has been proposed that insulin influences natriuretic peptide production.


The B-type natriuretic peptide is a useful biomarker for the estimation of volume overload in children with hypertension in children on peritoneal dialysis.

To evaluate the usefulness of serum B-type natriuretic peptide (BNP) as a biomarker of fluid retention in hypertensive children on peritoneal dialysis (PD).

Evolving use of natriuretic peptide receptor type-C as part of strategies for the treatment of pulmonary hypertension due to left ventricle heart failure.

Pulmonary hypertension (PH) due to left ventricular heart failure (LV-HF) is a disabling and life-threatening disease for which there is currently no single marketed pharmacological agent approved. Despite recent advances in the pathophysiological understanding, there is as yet no prospect of cure, and the majority of patients continue to progress to right ventricular failure and die. There is, therefore an urgent unmet need to identify novel pharmacological agents that will prevent or reverse the increase ...

Serum Chloride Levels Track with Survival in Patients with Pulmonary Arterial Hypertension.

Serum chloride is an important homeostatic biomarker in left heart failure, with significant prognostic implications. The impact of serum chloride in the long-term survival of pulmonary arterial hypertension (PAH) patients is unknown. We tested whether serum chloride levels are associated with long-term survival in PAH patients.

Effect of percutaneous transvenous mitral commissurotomy on brain natriuretic peptide in mitral stenosis in tertiary care hospitals of Peshawar.

The current study was planned to determine the effect of percutaneous transvenous mitral commissurotomy (PTMC) on brain natriuretic peptide (BNP) levels in mitral stenosis patients. It was conducted at the Postgraduate Medical Institute, Lady Reading Hospital, Peshawar, and Rehman Medical Institute Laboratory, Peshawar, Pakistan, from December 2013 to June 2014. Of the 100 patients, 63(63%) were females. The patients' age ranged from 14 to 58 years. Patients diagnosed with isolated mitral valve stenosis or ...

Neprilysin inhibitors as a new approach in the treatment of right heart failure in the course of chronic obstructive pulmonary disease.

The aim of the study was to find out scientific evidence on the possible use of the combined angiotensin II receptor antagonist and neprilysin inhibitors (ARNI) in patients with right heart failure (RHF) in the course of chronic obstructive pulmonary disease (COPD). It has been proven that a lack of neprilysin or its reduced expression in hypoxia leads to exacerbation of pulmonary arterial remodelling (PAR) or pulmonary hypertension (PH) in the mechanism related to the platelet-derived growth factor (PDGF) ...

Semaphorin 4D levels in heart failure patients: a potential novel biomarker of acute heart failure?

Semaphorin 4D (Sema4D) is expressed on platelets and T-cells and known to be involved in inflammation. The aims of this study include comparing Sema4D and N terminal pro brain natriuretic peptide (NT-proBNP) serum levels in heart failure (HF) patients to a control group, evaluating the correlation between Sema4D and NT-proBNP levels, and assessing Sema4D serum levels in HF patients during acute exacerbation and remission.

Involvement of brain natriuretic peptide signaling pathway in the cardioprotective action of sitagliptin.

The current study is focusing on the role of brain natriuretic peptide (BNP), a substrate of dipeptidyl peptidase-4 (DPP-4) enzyme, and its signaling survival pathway in the cardioprotective mechanism of sitagliptin, a DPP-4 inhibitor.

Alamandine attenuates hypertension and cardiac hypertrophy in hypertensive rats.

Oral administration of the peptide alamandine has antihypertensive and anti-fibrotic effects in rats. This work aimed to determine whether subcutaneous alamandine injection would attenuate hypertension and cardiac hypertrophy, and improve the function of a major target of hypertension-related damage, the left ventricle (LV), in spontaneously hypertensive rats (SHRs). This was examined in vivo in SHRs and normotensive rats subjected to 6-week subcutaneous infusion of alamandine or saline control, and in vitr...

Natriuretic peptides in human heart: Novel insight into their molecular forms, functions, and diagnostic use.

Among the three natriuretic peptides, atrial/A-type natriuretic peptide (ANP) and brain/B-type natriuretic peptide (BNP) are primarily produced by, and secreted from, heart tissue. They maintain cardiovascular homeostasis by binding to natriuretic peptide receptor-A. Since plasma ANP and BNP concentrations, as well as expression, are elevated in response to increased body fluid volume and pressure load on the heart wall, these peptides are widely utilized as diagnostic biomarkers for evaluating heart failur...

Obese Hypertensive Men Have Lower Circulating Proatrial Natriuretic Peptide Concentrations despite Greater Left Atrial Size.

Obese persons have lower circulating natriuretic peptide (NP) concentrations. It has been proposed that this natriuretic handicap plays a role in obesity-related hypertension. In contrast, hypertensive patients with left atrial enlargement have higher circulating NP concentrations. On this background, we investigated whether obese hypertensive men could have lower circulating NP concentrations despite evidence of pressure-induced greater left atrial size.

Predicting cardiogenic pulmonary edema in heart failure patients by using an N-terminal pro-b-type natriuretic peptide (NT-pro BNP) -based score.

Cardiogenic pulmonary edema (CPE) is a life-threatening emergency necessitating aggressive management. We conducted this study to test the hypothesis that a combination of N-terminal pro-b-type natriuretic peptide (NT-pro-BNP) and some relevant clinical factors may provide better predictability for CPE in heart failure (HF) patients.

MicroRNA-425 and microRNA-155 cooperatively regulate atrial natriuretic peptide expression and cGMP production.

Atrial natriuretic peptide (ANP), secreted primarily by atrial cardiomyocytes, decreases blood pressure by raising cyclic 3',5'-guanosine monophosphate (cGMP) levels and inducing vasorelaxation, natriuresis, and diuresis. Raising the level of ANP has been shown to be an effective treatment for hypertension. To advance the future development of an anti-microRNA (miR) approach to increasing expression of ANP, we investigated the regulation of NPPA expression by two miRs: miR-425 and miR-155. We examined wheth...

The right ventricular outflow tract in pediatric pulmonary hypertension-Data from the European Pediatric Pulmonary Vascular Disease Network.

The right ventricular outflow tract (RVOT) is pivotal for adequate RV function and known to be adversely affected by elevated pulmonary arterial pressure (PAP) in adults with pulmonary hypertension (PH). Aim of this study was to determine the effects of increased RV pressure afterload in children with PH on RVOT size, function, and flow parameters.

Nintedanib improves cardiac fibrosis but leaves pulmonary vascular remodeling unaltered in experimental pulmonary hypertension.

Pulmonary arterial hypertension (PAH) is associated with increased levels of circulating growth factors and corresponding receptors, such as PDGF, FGF and VEGF. Nintedanib, a tyrosine kinase inhibitor targeting primarily these receptors, is approved for the treatment of patients with idiopathic pulmonary fibrosis. Our objective was to examine the effect of nintedanib on proliferation of human pulmonary microvascular endothelial cells (MVEC) and assess its effects in rats with advanced experimental pulmonary...

Right ventricular functions in pulmonary thromboembolism.

this is a letter to editor We have read with great interest the paper entitled 'Subclinical Atherosclerosis in Patients with Prior Pulmonary Thromboembolism' Buyukterzi et al.1 is very important study. We have some suggestions about this trial. Firstly there are several echocardiographic parameters are available to determine right ventricular functions. Fractional area change (FAC), tricuspit annular plane systolic excursion (TAPSE), tissue Doppler derived right ventricular systolic excursion velocity S', s...

Atrial and brain natriuretic peptides: hormones secreted from the heart.

The natriuretic peptide family consists of three biologically active peptides: atrial natriuretic peptide (ANP), brain (B-type) natriuretic peptide (BNP), and C-type natriuretic peptide (CNP). Among these, ANP and BNP are secreted by the heart and act as cardiac hormones. Both ANP and BNP preferentially bind to natriuretic peptide receptor-A (NPR-A or guanylyl cyslase-A) and exert similar effects through increases in intracellular cyclic guanosine monophosphate (cGMP) within target tissues. Expression and s...

Comparison of Carbohydrate Antigen 125 and N-Terminal Pro-Brain Natriuretic Peptide for Risk Prediction After Transcatheter Aortic Valve Implantation.

Elevated carbohydrate antigen 125 (CA125) and N-terminal pro-brain natriuretic peptide (NTproBNP) have been associated with adverse outcome after transcatheter aortic valve implantation (TAVI). This study performs a comparison of both biomarkers for prognosis after TAVI. The study includes 363 patients. The primary end point was all-cause death or readmission for worsening congestive heart failure within 1 year after TAVI, and this end point occurred in 16% of the population. The optimal cutoff to predict t...

Circulating Protein Biomarkers in Systemic Sclerosis Related Pulmonary Arterial Hypertension: A Review of Published Data.

Pulmonary arterial hypertension (PAH) develops in 7-12% of patients with systemic sclerosis (SSc) and is associated with a 3 year survival of 52%. Early detection by screening is therefore recommended for all patients with SSc. Historically, screening has been performed using echocardiography and measurement of gas transfer. More recently the DETECT protocol, using a combination of biomarkers (including N-terminal pro-brain natriuretic peptide) and clinical parameters, has been developed. The optimal method...

Clinical diagnostic value of circulating serum miR-509-3p in pulmonary arterial hypertension with congenital heart disease.

Most pulmonary arterial hypertension (PAH) biomarkers are for risk stratification and prognosis prediction. We aimed to evaluate the diagnostic value of circulating serum miR-509-3p in PAH with congenital heart disease.

The importance of left heart disease as a cause of pulmonary hypertension in COPD.

Chronic obstructive pulmonary disease is a common respiratory condition that presents in varying degrees of severity and can be complicated by further co-morbidities. Up to a third can also have pulmonary hypertension, which is an important risk factor associated with an increase in morbidity and mortality. The etiology of the pulmonary hypertension contributes. Correctly considering and identifying the type of pulmonary hypertension will influence management and outcome in patients with COPD. The article b...

Serum albumin concentration as an independent prognostic indicator in patients with pulmonary arterial hypertension.

Serum albumin is a strong prognostic indicator for many disease processes, yet limited data exist regarding its prognostic relationship in pulmonary arterial hypertension (PAH). Our study aims to assess the relationship of hypoalbuminemia with disease severity and mortality in this population.

Progress in genetic research on primary pulmonary hypertension.

Primary pulmonary hypertension (PPH) consisting of hereditary pulmonary arterial hypertension and idiopathic pulmonary arterial hypertension is an obstructive pulmonary hypertension caused by primary pulmonary artery hyperplasia. Both environmental and genetic factors are involved in the pathogenesis of PPH. Genes associated with TGF-β signaling pathway including BMPR2, ALK1, ENG, SMAD8 and other genes including NFU1, CAV1, KCNK3 and TopBPl have been associated with PPH. In this review, the function and me...


Advertisement
Quick Search
Advertisement
Advertisement